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Summary To determine the level of antimalarial drug resistance in southern Papua, Indonesia,
we assessed the therapeutic efﬁcacy of chloroquine plus sulfadoxine—pyrimethamine (CQ+SP)
for Plasmodium falciparum infections as well as CQmonotherapy for P. vivax infections. Patients
with P. falciparum failing therapy were re-treated with unsupervised quinine±doxycycline
therapy and those with P. vivax with either unsupervised quinine±doxycycline or amodi-
aquine. In total, 143 patients were enrolled in the study (103 treated with CQ+SP and 40
with CQ). Early treatment failures occurred in four patients (4%) with P. falciparum and six
patients (15%) with P. vivax. The failure rate by Day 28 for P. vivax was 65% (95% CI 49—81).pyrimethamine;
Drug resistance;
Papua;
Indonesia
After PCR correction for re-infections, the Day 42 recrudescence rate for P. falciparum
infections was 48% (95% CI 31—65). Re-treatment with unsupervised quinine±doxycycline
resulted in further recurrence of malaria in 48% (95% CI 31—65) of P. falciparum infections and
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70% (95% CI 37—100) of P. vivax infections. Eleven patients with recurrent P. vivax were re-
treated with amodiaquine; there were no early or late treatment failures. In southern Papua, a
high prevalence of drug resistance of P. falciparum and P. vivax exists both to ﬁrst- and second-
line therapies. Preliminary data indicate that amodiaquine retains superior efﬁcacy compared
with CQ for CQ-resistant P. vivax.
pical Medicine and Hygiene. Published by Elsevier Ltd. All rights
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presence of a literate witness. All patients were given an
information sheet in their own language.© 2006 Royal Society of Tro
reserved.
. Introduction
he burden of malaria in Southeast Asia has been underap-
reciated by as much as 200% (Snow et al., 2005). Despite
he efforts of the Roll Back Malaria initiative, the situation
as deteriorated in the last 5 years as multidrug-resistant
trains of plasmodia continue to spread across malaria-
ndemic communities.
Whereas chloroquine (CQ)-resistant Plasmodium falci-
arum in Indonesia was ﬁrst documented over 30 years ago
Dondero et al., 1974), the emergence of drug-resistant
trains of P. vivax was only described in 1989 in north-
rn Papua Province (formerly Irian Jaya) on the eastern
order of the archipelago (Baird et al., 1991). Within 5
ears, the Day 28 failure rates following CQ therapy in this
egion had reached 95% for P. falciparum and 96% for P.
ivax (Sumawinata et al., 2003). Other studies of P. vivax
ave subsequently conﬁrmed a high prevalence of CQ resis-
ance both in northern Papua (Baird et al., 1997a; Murphy
t al., 1993; Taylor et al., 2001; Tjitra et al., 2002a) and
lsewhere in Indonesia (Baird et al., 1996; Fryauff et al.,
998). High rates of resistance to second-line treatment
sulfadoxine—pyrimethamine (SP)) have been reported in
apua both for P. falciparum (Tjitra et al., 2001, 2002a)
nd for P. vivax (Tjitra et al., 2002b). The combination of
Q+SP has had similarly poor efﬁcacy in northern Papua
oth against P. falciparum (Tjitra et al., 2002a) and P. vivax
Tjitra et al., 2002b).
Only one study has been published from southern Papua,
hich demonstrated that in 1992 52% of patients with
. falciparum had high-grade resistance (RII or RIII) to
Q monotherapy (Pribadi et al., 1998). In this study, in
itro sensitivity testing suggested that SP still retained
fﬁcacy against P. falciparum. Local policy in the Mimika
istrict of southern Papua was changed to advocate CQ+SP
or infections of P. falciparum and CQ monotherapy for
. vivax. However, in the ensuing decade a steady rise
n the number of reported cases of malaria in this region
espite a well-funded malaria control programme suggested
he sustained emergence of signiﬁcant antimalarial drug
esistance. In a small unpublished study in 2001, failure
ates by Day 28 of CQ+SP were 75% compared with 79%
or SP alone (Crouch-Chivers, personal communication).
he corresponding failure rates of CQ plus 3 days of pri-
aquine resulted in a Day 28 cure rate of 13% for P. vivax
nfections.
As part of a series of studies to rationalise antimalar-
al protocols in this region, we undertook a series of
hemotherapeutic trails to determine the efﬁcacy of
rotocols for uncomplicated falciparum and vivax malaria
hat were prevailing in 2004.
2
O
r. Materials and methods
.1. Study site
he study was carried out at an established rural outpatient
linic west of the city of Timika in southern Papua, Indone-
ia. This forested lowland area has unstable malaria trans-
ission associated with three mosquito vectors: Anopheles
oliensis, A. farauti and A. punctulatus (Lee et al., 1980;
ribadi et al., 1998). The annual incidence of malaria is 620
er 1000 per year, divided 55:45 between P. falciparum and
. vivax infections (Peter Ebsworth, personal communica-
ion). Owing to economic migration, the ethnic origin of the
ocal population is diverse, with highland Papuans, lowland
apuans and non-Papuans all resident in the region. In view
f the high number of infections in non-immune patients,
ocal protocols recommend that all patients with patent par-
sitaemia are given antimalarial therapy.
.2. Study design
his was a prospective, open-label drug efﬁcacy study of
rotocols recommended in 2004 for infections with P. falci-
arum (CQ+SP) and P. vivax (CQ) in children and adults with
ncomplicated symptomatic malaria. The study was based
n the 2003 WHO in vivo antimalarial drug sensitivity pro-
ocol (WHO, 2003), modiﬁed to include mixed infections.
atients were followed for 42 days in the falciparum arm
nd 28 days in the vivax arm using a standardised drug efﬁ-
acy record form.
.3. Patients
onsecutive patients with slide-conﬁrmed malaria (P. falci-
arum, P. vivax or mixed infections) with any parasitaemia
nd a fever or a history of fever during the preceding
8 h presenting to the outpatient clinic were enrolled in
he study. Exclusion criteria included pregnant or lactating
omen, children under 10 kg, patients with signs of sever-
ty (WHO, 2000), a parasitaemia >4% or concomitant disease
equiring hospital admission. Informed consent was signed
y an adult patient or by a parent/guardian for children.
f the subject was illiterate, consent was obtained in the.4. Study procedures
n admission, a standardised data sheet was completed
ecording demographic information, details of symptoms
nesia
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and their duration, and the history of previous antimalar-
ial medication. Clinical examination ﬁndings were docu-
mented, including axillary temperature measured using a
digital electronic thermometer. Venous blood was taken for
blood ﬁlm, haematocrit and white blood cell (WBC) count.
Parasite counts were determined on Giemsa-stained thick
ﬁlms as the number of parasites per 200 WBCs. All slides
were read by a certiﬁed microscopist with 10 years experi-
ence. A thick ﬁlm was considered negative on initial review
if no parasites were seen in 100 high power ﬁelds. A thin ﬁlm
was also examined to conﬁrm parasite species and used for
quantiﬁcation if parasitaemia was >200 per 200 WBCs. All
slides were cross-checked by another experienced micro-
scopist.
Patients were examined daily thereafter until they
became afebrile and aparasitaemic. At each visit, a
blood ﬁlm was taken and a symptom questionnaire was
completed. Patients were then seen weekly for 4 weeks
(P. vivax infections) or 6 weeks (P. falciparum or mixed
infections). Patients were also encouraged to return to
the clinic on any other day that they felt unwell. At each
clinic visit a full physical examination was performed,
the symptom questionnaire was completed and blood
was taken to check for parasite count and haemoglobin
level using a battery-operated portable photometer
(HemoCueTM Hb201+; HemoCue, Angelholm, Sweden).
Blood spots on ﬁlter paper (Whatman 3mm chromatography
paper) were also collected on Day 0 and on the day of
failure.
2.5. Plasma chloroquine levels
Heparinised venous blood samples were taken from patients
who agreed to be venipunctured on Days 0, 7, 28 or the
day of recrudescence. Samples were processed within
4 h of venipuncture, spun at 2000 rpm for 10min and
plasma was removed and stored at −20 ◦C until anal-
ysis. Plasma drug concentrations of CQ and its major
metabolite desethylchloroquine (DCQ) were assayed by
HPLC as described previously (Alvan et al., 1982). The
interassay coefﬁcients of variation for CQ and DCQ were,
respectively: 14.4% and 16.8% at 5 ng/ml (n = 6) and 2.5%
and 5.3% at 100 ng/ml (n = 6). The limit of quantitation
was 5 ng/ml for CQ and 2.5 ng/ml for DCQ. The minimum
effective concentration (MEC) of CQ+DCQ was deﬁned as
30 ng/ml plasma for P. falciparum and 15 ng/ml for P. vivax
(Baird, 2004). These concentrations correspond to the
whole blood concentrations used by other investigators
of 200 ng/ml and 100 ng/ml, respectively (Baird et al.,
1997b).
2.6. Treatment
Standard treatment courses of CQ+SP for P. falciparum
(alone or mixed with P. vivax) or CQ for pure P. vivax
infections were administered. The CQ+SP regimen consisted
of CQ (P.T. Bayer, Jakarta, Indonesia; 150mg base/tablet,
25mg/kg over 3 days) and SP was given as a single
dose on Day 0 (25mg/kg sulfadoxine and 1.25mg/kg
pyrimethamine). All drug administrations were supervised
and participants were observed for 30—60min to exclude
d
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dverse reactions and to ensure the medication was not
omited. If vomiting occurred within 60min, the whole dose
as repeated once. If vomiting occurred again within 60min,
he patient was withdrawn from the study. Paracetamol was
iven if the axillary temperature was ≥38 ◦C.
Those patients failing therapy were re-treated with qui-
ine (10mg of salt/kg body weight/dosage orally three times
day for 7 days) plus doxycycline (100mg twice a day for
days) if ≥8 years age and not pregnant. From May 2004,
hose patients with reappearance of P. vivax within 28 days
ere given a 3-day course of supervised amodiaquine if
hey consented (FlavoquineTM; Aventis, Basel, Switzerland;
00mg salt/150mg base per tablet, 30mg/kg over 3 days).
rimaquine (15mg base/kg of body weight for 14 days) was
dministered to those individuals with P. vivax infection or
ixed infection on Day 28 of their participation in the study.
.7. Endpoints
herapeutic response was determined using clinical and par-
sitological criteria. The primary endpoints were the ther-
peutic response on the basis of parasitological and clinical
ure by Day 28 for P. vivax infections and by Day 42 for P.
alciparum infections. The WHO criteria (WHO, 2003) were
odiﬁed to include P. falciparum genotyping to differentiate
ecrudescence from re-infection. The latter were distin-
uished according to polymorphisms in MSP-1, MSP-2 and
LURP, as described previously (Brockman et al., 1999). New
nfections detected by genotyping were classiﬁed as non-
reatment failures. New infections and indeterminate PCR
esults were excluded from the Day 28 or Day 42 failure rate
f the follow-up was terminated before the endpoint was
chieved. Since CQ concentrations persist at levels above
he MEC for P. vivax beyond 28 days (Baird et al., 1997b),
ny recurrence within this time was considered to be a ther-
peutic failure.
.8. Statistical analysis
ata were double entered and validated using EpiData
.02 software (EpiData Association, Odense, Denmark)
nd analysis was performed using SPSS for Windows (SPSS
nc., Chicago, IL, USA). The Mann—Whitney U-test or
ruskal—Wallis method were used for non-parametric
omparisons, and Student’s t-test or ANOVA were used for
arametric comparisons. For categorical variables, per-
entages and corresponding 95% CI were calculated using
ilson’s method. Proportions were examined using 2 with
ates’ correction or by Fisher’s exact test. In view of the
requent intercurrent infections with different species from
he original, we also performed a survival analysis in which
atients lost to follow-up or re-presenting with a different
pecies from their original infection were censored on the
ast day of follow-up and regarded as not being treatment
ailures. Failure rates were derived from the cumulative
ncidence of failure at Day 28 or Day 42. Thresholds for
eﬁning an inadequate threshold for parasite reduction
atio (PRR) at 24 h (parasitaemia on day 1/parasitaemia
n admission) were assessed using the receiver operator
urve and Youden’s Index calculated as sensitivity plus
peciﬁcity minus 1.
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.9. Ethics
he study was approved by the Ethics Committee of the
ational Institute of Health Research and Development, the
ndonesian Ministry of Health (Jakarta, Indonesia), the Ethics
ommittee of Menzies School of Health Research (Darwin,
ustralia) and the Oxford Tropical Research Ethics Commit-
ee. Informed consent was obtained from all adult partic-
pants and from parents of children. An independent Data
afety Monitoring Committee (DSMC) was established prior
o commencing the study and was asked to review the
rogress of the study after 100 patients had been enrolled.
he trial was registered with the clinical trials website
http://www.clinicaltrials.gov/ct) as NCT 00157859.
. Results
etween April and September 2004, 143 patients with
ncomplicated malaria were enrolled in the study. In total,
03 (72%) had P. falciparum infection alone or mixed with P.
ivax infection and were treated with CQ+SP. The remain-
ng 40 patients (28%) had pure P. vivax infections and were
reated with CQ monotherapy. Baseline characteristics are
iven in Table 1.
.1. Tolerability
arly vomiting within the ﬁrst hour of drug administration
ccurred in 8% of patients (8/103) treated with CQ+SP
nd 10% of patients (4/40) treated with CQ. Vomiting
fter CQ administration did not differ between the species
f infection, but was 7.2-fold (95% CI 1.7—31) higher in
hildren compared with adults: 19% (13/68) and 3% (2/75),
espectively (P = 0.003). In total, 6.3% of patients (9/143)
ere unable to tolerate their medication owing to recurrent
omiting (seven in the CQ+SP group and two in the CQ
roup), only one of whom was an adult. Five of these
f
B
h
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Table 1 Baseline characteristics of uncomplicated malaria study
P.
sul
No. of subjects enrolled 10
Males, % (n) 61
Age
Median (range) (years) 16
<5, % (n) 12
5—14, % (n) 35
>14, % (n) 53
Temperature >37.5 ◦C, % (n) 35
Splenomegaly, % (n) 84
Haemoglobin
Mean (SD) (g/dl) 10
<10 g/dl, % (n) 45
Geometric mean (95% CI) parasite count per l blood 18
Papuan ethnicity, % (n) 57A. Ratcliff et al.
atients tolerated changing medication to oral quinine,
ut two children required i.v. quinine. A further 7.0% of
atients (10/143) withdrew consent prior to completion of
herapy (four children and six adults). One patient with P.
ivax infection on admission was treated with CQ but was
ound to have mixed P. falciparum and P. vivax infection
n Day 1 and treatment was changed to quinine. The study
roﬁle is shown in Figure 1.
Of those subjects who received a full treatment course,
he mean dose of CQ administered was 27.6mg/kg (SD
.9mg) in the CQ+SP group and 26.3mg/kg (SD 2.6mg) in
he CQ group. Follow-up to Day 28 or day of failure in these
atients was achieved in 90% (77/86) of those treated with
Q+SP and 84% (31/37) following CQ administration.
.2. Early therapeutic response
arly treatment failure (ETF) with CQ+SP occurred in 4.2%
f patients (3/71) with P. falciparum infection compared
ith 6.7% of patients (1/15) with mixed infection (P = 0.5).
lthough ETF was more likely in patients with pure P. vivax
nfections treated with CQ (16%; 6/37), the difference did
ot reach statistical signiﬁcance (P = 0.06). Four patients
eveloped warning signs or markers of severity and required
escue with i.v. quinine. One adult with P. falciparum devel-
ped convulsions and coma, and one child with falciparum
alaria developed respiratory distress on Day 1. An adult
nd a child, both with vivax malaria, developed severe
omiting and diarrhoea on Day 1. The remaining six patients
ere categorised as having ETF due to delayed parasite
learance. Early treatment failure was 8.8-fold (95% CI
.7—28) higher in infants compared with older children and
dults (P < 0.001).
The median PRR at 48 h was 57 (range <1—1512) for P.
alciparum and 7.5 (range 1—180) for P. vivax (P < 0.001).
y Day 3, 29% of patients (8/28) infected with pure P. vivax
ad failed to clear their parasitaemia compared with 38%
5/13) of patients with mixed infection and 7% of patients
patients
falciparum (chloroquine+
fadoxine—pyrimethamine)
P. vivax (chloroquine)
3 40
% (63) 55% (22)
(1—60) 14.5 (1.6—60)
% (12) 28% (11)
% (36) 23% (9)
% (55) 50% (20)
% (36) 15% (6)
% (83/99) 79% (31/39)
.2 (1.9) 10.5 (2.1)
% (46) 38% (15)
51 (1241—2761) 584 (343—993)
% (59) 65% (26)
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fFigure 1 Study pr
(4/56) with pure P. falciparum (P = 0.004). However, fever
clearance times were generally rapid, with 97% of patients
(30/31) having defervesced within 48 h.
3.3. Late therapeutic responseDuring subsequent follow-up, recurrence of malaria was
observed in 65 patients, 39 of whom had P. falciparum,
18 had P. vivax and 8 had mixed infections (see Table 2).
Overall, 31% of patients (20/65) with recurrent para-
sitaemia were symptomatic at the time of treatment failure
f
C
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T
o
Table 2 Failure rates (95% CI) of patients according to initial spe
P
Early treatment failure 4
Failure rate by Day 7 1
Failure rate by Day 28 5
Failure rate by Day 42, overall 7
Failure rate by Day 42, PCR corrected 4
Median time to recrudescence (range) (days) 1
a Early treatment failures and reappearance of falciparum or mixed in
b Early treatment failures and reappearance of vivax or mixed infectio. *Day 28; **Day 42.
reporting malaise, fever or history of fever) and 54%
22/41) were anaemic (haemoglobin <10 g/dl). There were
o differences in symptoms observed between the species
f infection at the time of failure.
The cumulative Day 28 failure rate for P. falciparum was
8% (95% CI 46—69) compared with 74% (95% CI 50—98)
or patients with mixed infections and 65% (95% CI 49—81)
or pure vivax infections (Table 2). By Day 42, 70% (95%
I 56—83) of patients with either P. falciparum or mixed
nfection had had a recurrence of P. falciparum infection.
reatment failure by Day 42 following falciparum malaria
ccurred in 88% (95% CI 70—100) of children compared with
cies of infection
. falciparum/mixed P. vivax
.7% (1.8—11.4) 16% (7.7—31)
3% (5.7—20)a 28% (13—43)b
6% (44—68)a 65% (49—81)b
0% (56—83)a —
8% (31—65)a —
5 (1—43) 12 (1—22)
fections.
ns.
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iigure 2 Cumulative incidence of therapeutic failure in patie
nd P. falciparum with chloroquine plus sulfadoxine—pyrimetha
9% (95% CI 38—80) of adults (hazard ratio = 2.4, 95% CI
.3—4.3; P = 0.004). The same trend was apparent 28 days
fter treatment of vivax malaria: 82% (95% CI 64—100) of
hildren and 49% (95% CI 24—74) of adults (P = 0.004). Sur-
ival plots of the cumulative incidence rate of therapeutic
ailure are presented in Figure 2.
Parasite genotyping was performed in 77% of patients
33/43) with P. falciparum or mixed infections on enrolment
nd at treatment failure. In 17 cases the recurrent isolate
as identiﬁed as a true recrudescence, in 10 cases as a new
nfection and in 6 cases the result was indeterminate. The
ailure rate of P. falciparum by Day 42, corrected by PCR
nd including ETFs, was 48% (95% CI 31—65).
The initial speed of parasite reduction was correlated
ith subsequent treatment failure in patients infected with
. vivax but not with P. falciparum. The PRR of P. vivax 48 h
fter starting CQ therapy was 20 (range 4—180) for those
ivax successfully treated compared with 7 (range 1—148)
n those with recurrence of P. vivax by Day 28 (P = 0.05).
he PRR of P. vivax at 24 h was signiﬁcantly correlated
ith the day of recurrence (Pearson’s coefﬁcient = 0.53,
= 0.018). Using Youden’s Index, the best cut-off at 24 h was
PRR of 7.4; parasite reduction below this level predicted
ubsequent treatment failure with 70% sensitivity and 63%
peciﬁcity.
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Table 3 Plasma chloroquine levels
Day 0
Detectable levels, % (n)
Median concentration (range) (ng/ml)a
Day 7
Detectable levels, % (n)
Median concentration (range) (ng/ml)
Day of failure
Detectable levels, % (n)
Median concentration (range) (ng/ml)
a In those with detectable levels.ollowing treatment of Plasmodium vivax with chloroquine ()
().
.4. Chloroquine concentrations
n admission, 39% of patients (35/89) had measurable con-
entrations of plasma CQ (see Table 3). In 29% of patients
18/63) infected with P. falciparum or mixed infections and
n 27% of patients (7/26) presenting with vivax malaria,
lasma CQ concentrations were above the MEC. The plasma
Q concentrations on Day 7 were signiﬁcantly lower in chil-
ren (median 92 ng/ml, range 0—426 ng/ml) compared with
dults (median 232 ng/ml, range 0—578 ng/ml) (P = 0.0001)
ut did not differ by species of infection. The difference
as still apparent after excluding those with early vomit-
ng. Three patients (one adult and two children) had unde-
ectable CQ concentrations on Day 7; all of these patients
ailed therapy within 21 days.
Plasma samples were available for CQ analysis in 49%
f patients (23/47) who recrudesced with P. falciparum or
ixed infections. In these patients, the median concentra-
ion of CQ+DCQ was 43 ng/ml (range 0—242 ng/ml), exceed-
ng the MEC in 61% of cases (14/23). In patients with P. vivax,
Q concentrations were measured in 7 (39%) of 18 patients
uring follow-up. The median CQ+DCQ concentration on the
ay of recrudescence was 44 ng/ml (range 25—108 ng/ml),
ith all of these patients having concentrations in excess of
he MEC.
P. falciparum P. vivax
44% (28/63) 27% (7/26)
52.5 (9—215) 97 (27—208)
94% (33/35) 91% (10/11)
181 (0—578) 168 (0—426)
78% (18/23) 100% (7/7)
44 (0—242) 44 (25—108)
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3.5. Gametocyte carriage following treatment
On admission, gametocytes were present in 9% of patients
(8/87) infected with P. falciparum compared with 18%
(7/40) with P. vivax and 38% (5/13) with mixed infections
(P = 0.004). By Day 7, none of the patients with P. vivax
infections had gametocytes present on blood ﬁlm exami-
nation compared with 47% (32/68) following treatment of
P. falciparum and mixed infections (P < 0.001). Following P.
falciparum infection, gametocyte carriage was still present
in 29% of patients (7/24) on Day 28. At the time of recrudes-
cence, gametocytes were present in 34% of patients (22/64)
failing therapy, with no difference between species of infec-
tion.
3.6. Re-treatments
Overall, 49 patients with P. falciparum or mixed infections
had treatment failures (2 delayed parasite clearance and 47
with late recurrence). Four patients refused re-treatment. A
child aged 5 years who had a reappearance of P. falciparum
that was associated with vomiting and tachypnoea on Day
12 was treated with i.v. quinine as an inpatient. In total, 44
patients agreed to be re-treated with 7 days of unsupervised
quinine (28 adults also received doxycycline). There were no
ETFs but 67% of patients (22/33) successfully followed-up
had a reappearance of parasitaemia by Day 28 (14 patients
had P. falciparum, 5 patients had mixed infection and 3
patients had P. vivax infection). By Day 28 the uncorrected
failure rate of unsupervised quinine±doxycycline for P. fal-
ciparum was 48% (95% CI 31—65) in this cohort. There was
no signiﬁcant difference in those receiving monotherapy or
additional doxycycline.
Twenty-two patients had P. vivax treatment failures (4
delayed parasite clearance and 18 with late recurrences). A
16-year-old male re-presented on Day 22 with a recurrence
of P. vivax associated with tachypnoea and a 3-day history
of vomiting everything; he was treated as an inpatient. One
adult refused re-enrolment. In total, 20 patients (15 chil-
dren and 5 adults) agreed to re-treatment and follow-up.
Nine patients were re-treated with 7 days of unsupervised
quinine, of whom six were successfully followed-up: ﬁve
had a further reappearance of P. vivax and one had an
adequate parasitological response. Eleven patients were
re-treated with amodiaquine (30mg base/kg) over 3 days.
There were no ETFs. Three were successfully followed
to Day 28: two had an adequate parasitological response
and one child had a further reappearance of P. vivax
on Day 31.
4. Discussion
This study highlights that the antimalarial policy being
used in 2004 in southern Papua, Indonesia, was no longer
effective. Almost 5% of patients with P. falciparum or mixed
infections treated with CQ+SP and 16% of those infected
with P. vivax treated with CQ alone required early rescue
therapy. The failure rate for P. vivax had risen to 65% by
Day 28 and that for P. falciparum or mixed infections had
risen to 71% by Day 42. When this degree of resistance
became apparent, the study was referred to an independent
r
r
o
o
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SMC who felt that it was inappropriate to continue using
hese treatment regimens and the study was stopped.
hese failure rates were based on a per-protocol analysis
o deﬁne resistance levels of the parasite. In practice a
urther 6% of patients were intolerant of CQ and another
% failed to complete therapy. If one assumes that all
hese patients would have had a recurrence of malaria
uring the follow-up period, then the overall Day 42 cure
ate during the study period would have been nearer
2% for P. falciparum and mixed infections and 24% for P.
ivax. These levels of drug resistance are undermining the
ocal malaria control strategy and contributing a consid-
rable burden of mortality and morbidity upon the local
ommunities.
Efﬁcacy was signiﬁcantly lower in infants, who were 8.8
imes (95% CI 2.7—28) more likely to suffer an ETF. Older
hildren also had an increase risk of late treatment failure
f P. falciparum 2.4-fold (95% CI 1.3—4.3) higher compared
ith adults. This may be attributed in part to children being
ess tolerant of CQ therapy as demonstrated by 7.2-fold
95% CI 1.7—31) higher rates of early vomiting and 60% lower
lasma CQ levels on Day 7. However, as in other endemic
reas, the lower failure rates in adults are also likely to
epresent a degree of immunity helping to clear resistant
lood-stage parasites from the bloodstream (Price et al.,
998).
Previous studies in Papua New Guinea and Papua Indone-
ia have shown the coexistence of CQ-resistant strains of
. falciparum and P. vivax, but until recently the degree of
esistance of P. vivax has tended to lag behind that of P. fal-
iparum. Our data from southern Papua show CQ resistance
n P. vivax was signiﬁcantly worse than that of P. falciparum.
he 48-h PRR of 7.5 for P. vivax was signiﬁcantly lower than
he 57 observed for P. falciparum. These ﬁgures compare
ith 438 for CQ-sensitive P. vivax isolates from Thailand
Pukrittayakamee et al., 2000a) and 1000 for CQ-sensitive
. falciparum isolates (White et al., 1989). The P. vivax
RR at 24 h was correlated signiﬁcantly with the day of
ecurrence, hence the lower the early reduction in parasite
iomass the earlier the recrudescence of P. vivax. At 24 h, a
RR <7.4 predicted subsequent treatment failure with 70%
ensitivity and 63% speciﬁcity. This early marker of thera-
eutic efﬁcacy could have useful application in other areas
ndemic for P. vivax as a rapid assessment for CQ efﬁcacy.
Conducting an in vivo study in an endemic area is
onfounded by re-infection. However, in this study PCR
enotyping conﬁrmed that 63% of the P. falciparum treat-
ent failures were due to true recrudescence rather than
e-infection and the Day 42 corrected cure rate following
. falciparum or mixed infection was 52%. Determining in
ivo efﬁcacy of P. vivax is more difﬁcult since recurrence of
alaria can be due to recrudescence from the same isolate,
e-infection with a new isolate or relapse from hypnozoite
tages (White, 2002). A review of published records of early
linical trials demonstrated that CQ levels after a dose of
5mg/kg exceed the MEC of sensitive strains of P. vivax for
t least 28 days (Baird et al., 1997b). In this region, the ﬁrst
elapse is observed 17—21 days after therapy, with a further
elapse at approximately 42 days. Hence, any recurrence
f P. vivax within 28 days either represents recrudescence
r a breakthrough relapse of a drug-resistant isolate (Baird
t al., 1997b). In our study, the plasma concentrations of
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Q at Day 7 were high and all late reappearances of P. vivax
ith concomitant CQ levels occurred at concentrations of
Q above the recognised MEC (15 ng/ml). This adds further
vidence that the failure rates observed in our study
epresent true CQ-resistant P. vivax rather than poor drug
bsorption.
Although primaquine is ineffective against the asexual
tages of P. falciparum, it is effective against all stages of
. vivax and in combination with CQ may improve efﬁcacy
gainst blood stages of P. vivax (Baird et al., 1995). In our
tudy, the high level of CQ resistance against P. vivax was
ot anticipated and terminal eradication was delayed until
ay 28. It is possible that the addition of primaquine on
dmission might have facilitated early parasite clearance
nd prevented some of the ETFs. However, the efﬁcacy of
rimaquine against liver stages generally requires 7—14 days
f therapy (1mg/kg or 0.5mg/kg daily, respectively), a reg-
men to which adherence is poor in practice. Furthermore,
n Papua it is unlikely that co-administration of an unsuper-
ised 14-day course of primaquine would have prevented
elapse of resistant isolates at the tail end of CQ treatment
ecause of poor compliance with the lengthy primaquine
egimen (Baird and Rieckmann, 2003).
In 2004, second-line therapy for uncomplicated malaria
n Mimika district was a 7-day course of unsupervised qui-
ine (plus doxycycline if older than 8 years). In our study,
he numbers completing a 28-day follow-up following re-
reatment were small but highlighted the 48% failure rate
or P. falciparum and 70% for P. vivax. In Thailand where
ultidrug-resistant P. falciparum is highly prevalent, unsu-
ervised quinine therapy was associated with high failure
ates, but cure rates rose to 85% by Day 28 when the
rug was supervised (Pukrittayakamee et al., 2000b). Qui-
ine is poorly tolerated, reliably causing cinchonism, and
eeds to be administered three times a day for 7 days.
ence, although the poor efﬁcacy of this regimen might
epresent emergence of quinine-resistant isolates, a more
ikely explanation is treatment failure secondary to poor
dherence as well as the inability of quinine, a rapidly
liminated antimalarial, to prevent the ﬁrst relapse of P.
ivax (Pukrittayakamee et al., 2000a). In total, 11 patients
ith recrudescent P. vivax were retreated with amodiaquine
onotherapy. Early parasite clearance was rapid in all cases
ith no ETFs. Although only three patients were followed for
8 days, none failed therapy during this time. This is one of
he ﬁrst reports of the efﬁcacy of amodiaquine against CQ-
esistant strains. Although it suggests that its efﬁcacy may
e superior to CQ, further studies are needed to conﬁrm
his.
In summary, our ﬁndings highlight the high levels of treat-
ent failure both of ﬁrst- and second-line therapies for P.
alciparum and P. vivax in southern Papua. The current level
f resistance is likely to be the most important factor in the
nability of the established malaria control programme to
ecrease the large burden of disease. Alternative strategies
nvolving the use of artemisinin-based combination thera-
ies are in progress.onﬂicts of interest statement
he authors have no conﬂicts of interest concerning the work
eported in this paper.
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